Business Description
BridgeBio Pharma Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
2CL.Germany
•
BBIO.USA
Description
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.42 | |||||
| Equity-to-Asset | -1.19 | |||||
| Debt-to-Equity | -1.67 | |||||
| Debt-to-EBITDA | -3.85 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.94 | |||||
| Beneish M-Score | -3.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -26.9 | |||||
| 3-Year EPS without NRI Growth Rate | -18.7 | |||||
| 3-Year FCF Growth Rate | -31.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.3 | |||||
| 9-Day RSI | 48.56 | |||||
| 14-Day RSI | 48.7 | |||||
| 6-1 Month Momentum % | -7.28 | |||||
| 12-1 Month Momentum % | -78.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.46 | |||||
| Quick Ratio | 5.46 | |||||
| Cash Ratio | 5.07 | |||||
| Days Sales Outstanding | 4.88 | |||||
| Days Payable | 941.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.43 | |||||
| Operating Margin % | -593.26 | |||||
| Net Margin % | -561.78 | |||||
| ROA % | -55.96 | |||||
| ROIC % | -343.01 | |||||
| ROC (Joel Greenblatt) % | -1161.33 | |||||
| ROCE % | -57.1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.73 | |||||
| EV-to-EBIT | -5.62 | |||||
| EV-to-Forward-EBIT | -5.86 | |||||
| EV-to-EBITDA | -5.7 | |||||
| EV-to-Forward-EBITDA | -5.93 | |||||
| EV-to-Revenue | 27.93 | |||||
| EV-to-Forward-Revenue | 24.33 | |||||
| EV-to-FCF | -4.99 | |||||
| Earnings Yield (Greenblatt) % | -17.8 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBIO
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 90.67 | ||
| EPS (TTM) ($) | -3.49 | ||
| Beta | 0.62 | ||
| Volatility % | 95.3 | ||
| 14-Day RSI | 48.7 | ||
| 14-Day ATR ($) | 0.916613 | ||
| 20-Day SMA ($) | 10.7845 | ||
| 12-1 Month Momentum % | -78.93 | ||
| 52-Week Range ($) | 4.98 - 53.57 | ||
| Shares Outstanding (Mil) | 148.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BridgeBio Pharma Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
BridgeBio Pharma Inc Analysis
Share your researchHeadlines
See More
No news.